184 related articles for article (PubMed ID: 15930076)
1. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.
Straker D; Correll CU; Kramer-Ginsberg E; Abdulhamid N; Koshy F; Rubens E; Saint-Vil R; Kane JM; Manu P
Am J Psychiatry; 2005 Jun; 162(6):1217-21. PubMed ID: 15930076
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
Schneiderhan ME; Batscha CL; Rosen C
Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
Kagal UA; Torgal SS; Patil NM; Malleshappa A
J Pharm Pract; 2012 Jun; 25(3):368-73. PubMed ID: 22551560
[TBL] [Abstract][Full Text] [Related]
6. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics.
Panagiotopoulos C; Ronsley R; Kuzeljevic B; Davidson J
Can J Psychiatry; 2012 Jan; 57(1):34-44. PubMed ID: 22296966
[TBL] [Abstract][Full Text] [Related]
7. Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models.
Lin CC; Bai YM; Chen JY; Hwang TJ; Chen TT; Chiu HW; Li YC
J Clin Psychiatry; 2010 Mar; 71(3):225-34. PubMed ID: 19814949
[TBL] [Abstract][Full Text] [Related]
8. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
[TBL] [Abstract][Full Text] [Related]
10. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study.
Mackin P; Watkinson HM; Young AH
Diabetologia; 2005 Feb; 48(2):215-21. PubMed ID: 15688206
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review.
Wysokiński A; Kowman M; Kłoszewska I
Psychiatr Danub; 2012 Sep; 24(3):314-22. PubMed ID: 23013638
[TBL] [Abstract][Full Text] [Related]
13. Metabolic risk in selected second-generation antipsychotics.
Kerna V; Nosalova G; Ondrejka I
Bratisl Lek Listy; 2010; 111(12):640-3. PubMed ID: 21384731
[TBL] [Abstract][Full Text] [Related]
14. Improvement of metabolic risk profile under second-generation antipsychotics: a pilot intervention study.
Blouin M; Binet M; Bouchard RH; Roy MA; Després JP; Alméras N
Can J Psychiatry; 2009 Apr; 54(4):275-9. PubMed ID: 19321034
[TBL] [Abstract][Full Text] [Related]
15. Application of three-dimensional body scanner: observation of prevalence of metabolic syndrome.
Lin JD; Chiou WK; Weng HF; Fang JT; Liu TH
Clin Nutr; 2004 Dec; 23(6):1313-23. PubMed ID: 15556253
[TBL] [Abstract][Full Text] [Related]
16. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.
Lin CC; Bai YM; Wang YC; Chen TT; Lai IC; Chen JY; Chen SY; Gau SS; Liou YJ
J Clin Psychopharmacol; 2009 Dec; 29(6):529-36. PubMed ID: 19910716
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome in an Italian psychiatric sample: a retrospective chart review of inpatients treated with antipsychotics.
Santini I; Stratta P; D'Onofrio S; De Lauretis I; Santarelli V; Pacitti F; Rossi A
Riv Psichiatr; 2016; 51(1):37-42. PubMed ID: 27030348
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome and mental illness.
Newcomer JW
Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
[TBL] [Abstract][Full Text] [Related]
19. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability.
de Kuijper G; Mulder H; Evenhuis H; Visser F; Hoekstra PJ
J Clin Psychopharmacol; 2013 Aug; 33(4):520-4. PubMed ID: 23775048
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics.
Centorrino F; Masters GA; Talamo A; Baldessarini RJ; Öngür D
Hum Psychopharmacol; 2012 Sep; 27(5):521-6. PubMed ID: 22996619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
